Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Am J Transplant ; 23(6): 844-847, 2023 06.
Article in English | MEDLINE | ID: covidwho-2252571

ABSTRACT

Peripheral allogeneic hematopoietic stem cell transplant recipients are the most vulnerable patients to community-acquired respiratory viruses such as respiratory syncytial virus, influenza virus, or others. These patients are likely to develop severe acute viral infections; community-acquired respiratory viruses have also been identified as triggers of bronchiolitis obliterans (BO). BO is a manifestation of pulmonary graft-versus-host disease, most often leading to irreversible ventilatory impairment. To date, there are no data on whether Severe acute respiratory syndrome â€‹coronavirus 2 (SARS-CoV-2) could be a trigger for BO. Here, we report the first report of a case of bronchiolitis obliterans syndrome following SARS-CoV-2 infection occurring 10 months after allogeneic hematopoietic stem cell transplant with a flare of underlying extra thoracic graft-versus-host disease. This observation provides a new perspective and should be of particular interest to clinicians, suggesting the need for close monitoring of pulmonary function test (PFTs) after SARS-CoV-2 infection. The mechanisms leading to bronchiolitis obliterans syndrome after SARS-CoV-2 infection require further investigation.


Subject(s)
Bronchiolitis Obliterans Syndrome , Bronchiolitis Obliterans , COVID-19 , Graft vs Host Disease , Hematopoietic Stem Cell Transplantation , Humans , SARS-CoV-2 , Bronchiolitis Obliterans/etiology , Hematopoietic Stem Cell Transplantation/adverse effects
2.
Respir Med Res ; 81: 100913, 2022 May.
Article in English | MEDLINE | ID: covidwho-2114708

ABSTRACT

BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is the main limitation to long-term survival following lung transplantation. Several studies generated promising results regarding the efficacy of extracorporeal photopheresis (ECP) in BOS management. We aimed to compare FEV1 evolution in ECP-treated versus non-ECP treated patients among BOS recipients. METHODS: Overall, 25 BOS patients were included after receiving optimized treatment. Data were collected retrospectively. Twelve patients with moderate and refractory BOS received ECP treatment. RESULTS: Among non-ECP treated control patients (n = 13), six experienced persistent decline without undergoing ECP for various reasons. ECP stabilized pre-ECP lung function during the subsequent 6 to 24 months (repeated measures one-way Anova, p = 0.002), without any significant impact observed by either FEV1 decline speed prior to ECP or time between BOS diagnosis and ECP onset. ECP-treated patients displayed a similar risk of an additional permanent 20% or higher drop in FEV1 after BOS onset compared to controls, but a lower risk compared to control decliners (p = 0.05). ECP quickly stabilized FEV1 decline in refractory BOS patients compared to non-treated decliners. CONCLUSIONS: We confirmed that this therapeutic option against refractory BOS can be managed in a medium-size LTx center, with a satisfactory efficacy and an acceptable tolerance.


Subject(s)
Bronchiolitis Obliterans , Lung Transplantation , Photopheresis , Bronchiolitis Obliterans/etiology , Bronchiolitis Obliterans/therapy , Humans , Lung Transplantation/adverse effects , Photopheresis/adverse effects , Photopheresis/methods , Retrospective Studies , Syndrome
3.
J Korean Med Sci ; 37(31): e246, 2022 Aug 08.
Article in English | MEDLINE | ID: covidwho-1987463

ABSTRACT

Coronavirus disease 2019 (COVID-19) is usually less severe in children and adolescents than in adults. However, it can cause severe respiratory illness in a small proportion of children with risk factors. Here, we report a rare case of a 10-year-old boy with postinfectious bronchiolitis obliterans that developed after pneumonia caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This patient was previously healthy apart from a high body mass index (BMI, 30.13; 99.6th percentile for the age bracket), history of preterm birth (35 weeks), and low birth weight (1,850 g). He had persistent exertional dyspnea after recovering from SARS-CoV-2-related pneumonia. Spirometry revealed obstructive lung disease with the following results: predicted forced vital capacity (FVC%pred), 71%; forced expiratory volume in 1 second (FEV1%pred), 63%; FEV1/FVC, 0.81; and forced expiratory flow25-75%pred, 55%. Chest computed tomography showed multifocal areas of parenchymal hyperlucency and mosaic attenuation in both lungs. This case suggests that careful observation of children with obesity and low birth weight is necessary after recovery from SARS-CoV-2-related pneumonia.


Subject(s)
Bronchiolitis Obliterans , COVID-19 , Pneumonia , Premature Birth , Adolescent , Adult , Bronchiolitis Obliterans/diagnosis , Bronchiolitis Obliterans/etiology , COVID-19/complications , Child , Female , Forced Expiratory Volume , Humans , Infant, Newborn , Lung/diagnostic imaging , Male , Pneumonia/complications , SARS-CoV-2 , Spirometry , Vital Capacity
4.
Interact Cardiovasc Thorac Surg ; 35(1)2022 06 15.
Article in English | MEDLINE | ID: covidwho-1908815

ABSTRACT

Lung transplants are still limited by the shortage of suitable donor lungs, especially during the coronavirus disease 2019 pandemic. A heterotopic lung transplant (HLTx), as a flexible surgical procedure, can maximize the potential of donor lungs in an emergency, but its widespread use is hindered by difficulties in anastomosis and paucity of outcome data. We performed a retrospective review of 4 patients, each of whom received an HLTxs over 1 year, including 1 left-to-right single HLTx, 2 right-to-left single HLTxs and 1 lobar HLTx (right upper lobe-to-left). The median recipient age was 58.5 years (46-68); 3 patients were male. The postoperative hospital stay was 33 days (30-42). One recipient lived for 10 years and died of bronchiolitis obliterans syndrome; the others were alive with no major morbidity at 12 to 31 months after the operation with a 1-year survival of 100%. The follow-up chest images showed that transplanted lungs could be inflated well and adapted morphologically to fill the thoracic cavity in the short and long term. This study demonstrates that an HLTx is a feasible alternative to a conventional lung transplant in emergency cases and could be considered in selected patients at advanced medical centres.


Subject(s)
Bronchiolitis Obliterans , COVID-19 , Lung Transplantation , Tissue and Organ Procurement , Aged , Female , Humans , Lung , Lung Transplantation/adverse effects , Lung Transplantation/methods , Male , Middle Aged , Retrospective Studies
5.
Transplant Proc ; 54(6): 1564-1568, 2022.
Article in English | MEDLINE | ID: covidwho-1867842

ABSTRACT

BACKGROUND: Since December 2019, the SARS-CoV-2 pandemic significantly has impacted the medical community. When infected with SARS-CoV-2, most of the patients developed bilateral pneumonia. We have herein presented the atypical case of a patient who developed unilateral SARS-CoV-2 pneumonia, affecting only the second lung allograft re-transplanted (re-LTX). CASE PRESENTATION: A SARS-CoV-2 infection occurred in a 2-dose vaccinated patient with LTx with a history of second unilateral lung transplantation performed after an end-stage bronchiolitis obliterans syndrome. The first symptoms started with a flu-like syndrome, and the patient's clinical condition worsened with nonsevere acute respiratory failure requiring conventional oxygen therapy. Treatment consisted in administrating specific anti-SARS-CoV-2 monoclonal antibodies along with probabilistic antibiotherapy, anticoagulation, and steroids. On day 7, the patient was discharged from hospital. We aimed to assess this atypical unilateral pneumonia based on different explorations. A ventilation scintigraphy showed a severe ventilation decrease owing to end-stage bronchiolitis obliterans syndrome within the left first allograft, which may be associated with asymmetrical virus diffusion between the 2 lungs. We did not identify any other relevant differences with respect to the 2 donors' clinical characteristics. Using specific immunohistochemistry staining against angiotensin converting enzyme-2 receptor, the main known receptor for SARS-CoV-2 binding on airway epithelial cells, no staining difference was observed between the 2 lung biopsies that were collected at re-LTx from each lung. CONCLUSIONS: With the present case report, we aimed to highlight how this kind of unusual presentation may be caused by the difference of ventilation between the 2 lungs.


Subject(s)
Bronchiolitis Obliterans , COVID-19 , Influenza, Human , Lung Diseases, Interstitial , Pneumonia, Mycoplasma , Antibodies, Monoclonal , Antibodies, Viral , Anticoagulants , Bronchiolitis Obliterans/pathology , Humans , Lung/diagnostic imaging , Lung/pathology , Oxygen , Peptidyl-Dipeptidase A , SARS-CoV-2
6.
Front Public Health ; 9: 705225, 2021.
Article in English | MEDLINE | ID: covidwho-1775819

ABSTRACT

Coffee production is a global industry with roasteries throughout the world. Workers in this industry are exposed to complex mixtures of gases, dusts, and vapors including carbon monoxide, carbon dioxide, coffee dust, allergens, alpha-diketones, and other volatile organic compounds (VOCs). Adverse respiratory health outcomes such as respiratory symptoms, reduced pulmonary function, asthma, and obliterative bronchiolitis can occur among exposed workers. In response to health hazard evaluations requests received from 17 small- to medium-sized coffee facilities across the United States, the National Institute for Occupational Safety and Health conducted investigations during 2016-2017 to understand the burden of respiratory abnormalities, exposure characteristics, relationships between exposures and respiratory effects, and opportunities for exposure mitigation. Full-shift, task-based, and instantaneous personal and area air samples for diacetyl, 2,3-pentanedione and other VOCs were collected, and engineering controls were evaluated. Medical evaluations included questionnaire, spirometry, impulse oscillometry, and fractional exhaled nitric oxide. Exposure and health assessments were conducted using standardized tools and approaches, which enabled pooling data for aggregate analysis. The pooled data provided a larger population to better address the requestors' concern of the effect of exposure to alpha-diketones on the respiratory heath of coffee workers. This paper describes the rationale for the exposure and health assessment strategy, the approach used to achieve the study objectives, and its advantages and limitations.


Subject(s)
Bronchiolitis Obliterans , Occupational Exposure , Bronchiolitis Obliterans/etiology , Coffee/adverse effects , Diacetyl/adverse effects , Diacetyl/analysis , Food Industry , Humans , Occupational Exposure/adverse effects , Occupational Exposure/analysis , United States
7.
Pediatr Pulmonol ; 56(7): 2381-2384, 2021 07.
Article in English | MEDLINE | ID: covidwho-1212779

ABSTRACT

During the COVID-19 pandemic, management of SARS-CoV-2 infection in children with underlying chronic lung disease has been challenging. There are limited studies in children with respiratory comorbidities, apart from asthma, presumably due to low morbidity of SARS-CoV-2 infection in the general pediatric population along with the low incidence of certain pulmonary conditions. Compassionate use of remdesivir has been shown to reduce time to clinical improvement in adults and has been retrospectively studied in small pediatric cohorts with promising results. Whether children with underlying respiratory conditions may benefit from antiviral treatment in the context of different pathophysiologic backgrounds and unknown drug safety and efficacy needs to be further evaluated. We present a case of COVID-19 infection in a 3-year old toddler with severe postinfectious bronchiolitis obliterans, who received compassionate treatment with 5-day-course of remdesivir, and recovered with favourable outcome.


Subject(s)
Bronchiolitis Obliterans , COVID-19 , Adenosine Monophosphate , Adult , Alanine , Antiviral Agents/therapeutic use , Bronchiolitis Obliterans/complications , Bronchiolitis Obliterans/diagnosis , Bronchiolitis Obliterans/drug therapy , Child , Child, Preschool , Humans , Pandemics , Retrospective Studies , SARS-CoV-2
8.
Saudi Med J ; 42(4): 391-398, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-1168263

ABSTRACT

OBJECTIVES: To determine the demographic and clinical characteristics, underlying comorbidities, and outcomes of children with coronavirus disease 2019 (COVID-19) infection. METHODS: In this retrospective study, we reported 62 pediatric patients (age <14 years) with confirmed COVID-19 between March 2 and July 1, 2020, at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. RESULTS: Comorbid conditions, including cardiac, neurological, respiratory, and malignant disorders, were reported in 9 patients (14.5%). The most prominent presenting complaints were fever (80.6%) and cough (48.4%). Most of our patients (80.6%) had mild disease, 11.3% had moderate disease, and 8.1% exhibited severe and critical illness. Twenty-one patients (33.9%) were hospitalized, with 4 patients (6.5%) admitted to the pediatric intensive care unit, and 3 (4.8%) patients died. CONCLUSION: All pediatric age groups are susceptible to COVID-19, with no gender difference. COVID-19 infection may result in critical illness and even mortality in subsets of pediatric patients.


Subject(s)
COVID-19/physiopathology , Abdominal Pain/physiopathology , Adolescent , Asthma/epidemiology , Atrophy , Brain/pathology , Bronchiolitis Obliterans/epidemiology , COVID-19/blood , COVID-19/epidemiology , COVID-19/therapy , Child , Child, Preschool , Comorbidity , Cough/physiopathology , Diarrhea/physiopathology , Dyspnea/physiopathology , Female , Fever/physiopathology , Heart Defects, Congenital/epidemiology , Hospital Mortality , Hospitalization , Humans , Hydrocephalus/epidemiology , Infant , Intensive Care Units, Pediatric , Male , Pharyngitis/physiopathology , Respiration, Artificial , Respiratory Insufficiency/physiopathology , Respiratory Insufficiency/therapy , Retrospective Studies , Rhinorrhea/physiopathology , SARS-CoV-2 , Saudi Arabia/epidemiology , Severity of Illness Index , Vomiting/physiopathology
9.
Transpl Infect Dis ; 23(2): e13480, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-804849

ABSTRACT

Exosomes isolated from plasma of lung transplant recipients with allograft injury contain donor-derived lung self-antigens (collagen V and Kα1 tubulin) and human leukocyte antigen (HLA) molecules. We present a case of a 76-year-old, female lung transplant recipient treated for acute cellular rejection with methylprednisolone and anti-thymocyte globulin, who subsequently contracted SARS-CoV-2 and developed a sharp increase in the mean fluorescent intensity of anti-HLA antibodies. Analysis of circulating exosomes during rejection, but before SARS-CoV-2 infection, revealed the presence of lung self-antigens and HLA class II molecules. After the patient contracted SARS-CoV-2, exosomes with the SARS-CoV-2 spike protein were also found. After resolution of infectious symptoms, exosomes with SARS-CoV-2 spike protein were no longer detected; however, exosomes with lung self-antigens and HLA class II molecules persisted, which coincided with a progressive decline in spirometric flows, suggesting chronic lung allograft dysfunction. We propose that the analysis of circulating exosomes may be used to detect allograft injury mediated by both rejection and infection. Furthermore, the detection of exosomes containing viral proteins may be helpful in identifying allograft injury driven by viral pathogens.


Subject(s)
COVID-19/metabolism , Exosomes/metabolism , Graft Rejection/drug therapy , Histocompatibility Antigens Class II/metabolism , Immunosuppressive Agents/adverse effects , Lung Transplantation , Spike Glycoprotein, Coronavirus/metabolism , Aged , Antilymphocyte Serum/therapeutic use , Autoantigens/immunology , Autoantigens/metabolism , Bronchiolitis Obliterans , COVID-19/immunology , Collagen Type V/immunology , Collagen Type V/metabolism , Disease Progression , Female , Glucocorticoids/adverse effects , Glucocorticoids/therapeutic use , HLA Antigens/immunology , HLA Antigens/metabolism , Histocompatibility Antigens Class II/immunology , Humans , Immunosuppressive Agents/therapeutic use , Methylprednisolone/adverse effects , Methylprednisolone/therapeutic use , SARS-CoV-2/immunology , SARS-CoV-2/metabolism , Spike Glycoprotein, Coronavirus/immunology , Tubulin/immunology , Tubulin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL